November 18, 2005
Running Time: 00:55:30
Intellectual property restrictions rarely impose burdens on genomic and proteomic research, but there are reasons to be apprehensive about their future impact on advances in this field, says a new report from the National Research Council. Policy-makers should take steps to prevent the increasingly complex web of intellectual property protections from getting in the way of potential biomedical breakthroughs.
Shirley Tilghman, president, Princeton University, Princeton, N.J. and Roderick McKelvie, partner, Covington & Burling, Washington, D.C.